In this study, we therefore evaluated the effect of RAS inhibitors and SGLT2 inhibitors with the annual eGFR decline rate as an evaluation index on patients with T2DM without albuminuria. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.